

# Accepted Manuscript

Microwave-Assisted Oxidation of Indan-1-ones into Ninyhydrins

Christelle Marminon, Abdelhamid Nacereddine, Zouhair Bouaziz, Pascal Nebois, Joachim Jose, Marc Le Borgne

PII: S0040-4039(15)00367-6

DOI: <http://dx.doi.org/10.1016/j.tetlet.2015.02.086>

Reference: TETL 45956

To appear in: *Tetrahedron Letters*

Received Date: 21 November 2014

Revised Date: 6 February 2015

Accepted Date: 18 February 2015




Please cite this article as: Marminon, C., Nacereddine, A., Bouaziz, Z., Nebois, P., Jose, J., Borgne, M.L., Microwave-Assisted Oxidation of Indan-1-ones into Ninyhydrins, *Tetrahedron Letters* (2015), doi: <http://dx.doi.org/10.1016/j.tetlet.2015.02.086>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Graphical Abstract****Microwave-Assisted Oxidation of  
Indan-1-ones into Ninhhydrins**

Leave this area blank for abstract info.

Christelle Marminon\*, Abdelhamid Nacereddine, Zouhair Bouaziz, Pascal Nebois, Joachim Jose and Marc Le Borgne





## Microwave-Assisted Oxidation of Indan-1-ones into Ninhydrins

Christelle Marminon\*<sup>a</sup>, Abdelhamid Nacereddine<sup>a</sup>, Zouhair Bouaziz<sup>a</sup>, Pascal Nebois<sup>a</sup>, Joachim Jose<sup>b</sup> and Marc Le Borgne<sup>a</sup>

<sup>a</sup> Université de Lyon, Université Lyon 1, Faculté de Pharmacie - ISPB, EA 4446 Biomolécules Cancer et Chimiorésistances, SFR Santé Lyon-Est CNRS UMS3453 - INSERM UST, 8 avenue Rockefeller, F-69373, Lyon Cedex 8, France

<sup>b</sup> Institute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, Westfalian Wilhelms-University Münster, Corrensstr. 48, 48149 Münster, Germany

### ARTICLE INFO

*Article history:*

Received

Received in revised form

Accepted

Available online

### ABSTRACT

A simple and general microwave-assisted selenium oxidation has been developed for the synthesis of substituted ninhydrins from indan-1-ones in order to access to indeno[1,2-*b*]indoles substituted on the A ring. This efficient and convenient oxidation, using selenium dioxide under microwave irradiations, afforded mono- and di-substituted ninhydrins in a single step reaction with good yields.

*Keywords:*

Ninhydrin

Oxidation


Microwave-assisted synthesis

Indan-1-one

Selenium dioxide.

2009 Elsevier Ltd. All rights reserved.

Protein kinase CK2 (formally termed casein kinase 2) is an essential, ubiquitous serine/threonine kinase which is highly pleiotropic, and constitutively active.<sup>1</sup> A high activity of this protein has been reported in many human diseases<sup>2</sup> such as inflammatory disease processes, neurodegenerative disorders, viral infections and cardiovascular diseases. Moreover, CK2 has been associated with the proliferative status of several tumor cells from breast, colon, kidney, lung, pancreas and prostate.<sup>3</sup> In most cases a remarkable hyperactivity of CK2 has been observed.




**Figure 1** 5-Isopropyl-5,6,7,8-tetrahydroindeno[1,2-*b*]indole-9,10-(5*H*,6*H*)dione (**I**)

To date, numerous compounds have been identified as CK2 inhibitors.<sup>4</sup> Among them, the indeno[1,2-*b*]indole derivatives have revealed a great interest as ATP-competitive inhibitors,<sup>5</sup> effectively reducing cell viability and causing cell death. These compounds consist of small and planar heterocyclic scaffolds, which are able to fit into the nucleotide-binding pocket of CK2α and displace the ATP. The most potent CK2 inhibitor (**I**) (Figure 1) in this series inhibits the human CK2 with an IC<sub>50</sub> of 0.11 μM

and presents very good kinase selectivity.<sup>6</sup>

Its preparation was achieved in two steps from commercial ninhydrin, following the general pathway (R=H) which is described in the retrosynthetic scheme 1.<sup>7</sup>


In order to draw up Structure-Activity Relationships (SAR) to evaluate the influence of the nature and the position of substituants on the A ring, the synthesis of new substituted ninhydrins derivatives (R= OH, OMe, NO<sub>2</sub>, Br, F, CF<sub>3</sub>) was undertaken.



**Scheme 1** Retrosynthetic Analysis of Indeno[1,2-*b*]indole Derivatives

Ninhydrin (2,2-dihydroxyindane-1,3-dione) is well-known in particular owing to its color-forming reaction with amines.<sup>8</sup> Due to this property, numerous ninhydrins analogues have been reported for their use as latent fingerprint detectors in forensic science.<sup>9</sup> Ninhydrins are also used for the synthesis of heterocyclic compounds.<sup>10</sup> They are usually prepared by oxidation of indan-1-ones or indane-1,3-diones (Scheme 2).

\* Corresponding author: Tel.: +33 (0)478 77 28 59; Fax: +33 (0)478 77 28 67.  
E-mail address: christelle.marminon@univ-lyon1.fr (C. Marminon)




Scheme 2 Retrosynthetic Analysis of Ninyhydrins

Indan-1-ones are widely described as synthetic intermediates.<sup>11</sup> In addition, many of them are commercially available which prompted us to use them as starting material. Different methods are reported in the literature to oxidize indan-1-ones into 1,2,3-triones<sup>12</sup> which lead, in the presence of water, to an equilibrium with their more stable monohydrated form, the ninhydrin (Scheme 2).<sup>13</sup>

A first approach applies a sequence bromination / Kornblum-type oxidation of indan-1-ones (Scheme 3).<sup>9b, 10c, 14</sup>

An alternative way allows direct oxidation of indan-1-ones into ninhydrins by selenium dioxide, which is the most common reagent used for oxidation of alkyl fragments, in particular to convert mono carbonyl derivatives into 1,2-dicarbonyl compounds.<sup>15</sup> 5-O-alkylated ninhydrins were prepared with good yields (54-81%) using from 3 to 5 equivalents of selenium dioxide in dioxane at reflux for 3 to 6 hours.<sup>16</sup>




Scheme 3 Ninyhydrins Syntheses from Indan-1-ones

Microwave-assisted organic synthesis (MAOS) takes on great interest, which is evidenced by the large number of papers and reviews describing decreased reaction time, limited waste, increased yield and limited degradation.<sup>17</sup> This non-classical heating technique has been adopted in many academic and industrial laboratories. Moreover, selenium dioxide oxidation by closed-vessel microwave is reported to accelerate the synthesis of 1,2-dicarbonyl compounds.<sup>18</sup> A first attempt to oxidize 5-bromoindan-1-one using 3.1 equivalents of selenium dioxide in a sealed vessel under microwave heating in a Biotage Initiator Microwave synthesizer 2.0 440 W, at 170 °C in dioxane for ninety seconds afforded the 5-bromoninhydrin **2j** with 60% yield. This yield was significantly higher than the 23% yield obtained by Joullié *et al.* using 6-bromoindan-1-one and 5 equivalents of selenium dioxide, in dioxane at reflux for 2h.<sup>9b</sup> No workup was required: purification was simplified by a better conversion of selenium to selenium black. The product was only purified by column chromatography using solid deposit.

This result led us to explore the oxidation of indan-1-one **1a** to ninhydrin **2a** under microwave heating by varying the time and the number of equivalents of selenium dioxide (Table 1).

Table 1 Optimization of Reaction Conditions



Entry	$\text{SeO}_2$ (equiv.)	Water	Temp. (°C)	Time (min)	Yield %
1	3.1	-	classic, 100	45	64
2	3.1	-	classic, 100	210	71
3	3.1	-	MW, 180	1.5	72
4	3.1	-	MW, 180	5	78
5	3.1	-	MW, 180	10	81
6	2.5	-	MW, 180	5	67
7	4.6	-	MW, 180	5	79
8	3.1	10%	MW, 180	5	84
9	3.1	10%	MW, 180	10	85
10	3.1	10%	sealed-vessel, 180	5	33
11	3.1	10%	sealed-vessel, 180	20	77

Conventional and microwave heating (Table 1, entries 1-3) were first compared. The same yield was obtained even though microwave process remarkably reduced the reaction time (210 minutes to 1.5 minute). The increase in microwave irradiation time (Table 1, entries 3-5) improved the yields (from 72 to 81%). Variation of the number of equivalents of selenium dioxide (Table 1, entries 4, 6 and 7) pointed out that 3.1 equivalents were necessary but sufficient. The addition of water (10%) also improved the yield (Table 1, compare entries 4 to 8 and 5 to 9), which was probably due to the more elevated pressure in the vessel (8 bar to 13-16 bar). These conditions allowed us to get roughly the same yield, as the reaction time lasted five or ten minutes (Table 1, compare entries 8 and 9), which suggests that five minutes are sufficient.

In order to evaluate the influence of the thermal character, we applied the best conditions 8, using a sealed-vessel heated conventionally at 180°C for 5 and 20 minutes respectively (Table 1, entries 10 and 11). The yields were systematically lower, (77 % versus 84 %) suggesting a role of microwaves in this oxidation.

Then, to assess the scope of this method, we applied entry 8 to several substituted indan-1-ones. All ninhydrins (Table 2) were obtained with good to excellent yields (66-87%), always enhanced compared to those reported in the literature, after a purification step.<sup>19</sup> This closed-vessel microwave selenium dioxide oxidation has proved to be a general and convenient method.

In conclusion, we improved the classical oxidation conditions of indan-1-ones into ninhydrins by using microwave irradiations. We developed a rapid, convenient and general oxidation method, limiting amounts of selenium dioxide. These conditions, applied to substituted indan-1-ones, will be used to rapidly and easily

prepare diverse substituted ninhydrins in a single step with very good yields.

**Table 2** Oxidation of Several Indan-1-ones

Ninhydrin 2	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	Yield (%)	Yield (%) lit.	N° ref. lit.
2a	H	H	H	H	84	85 <sup>a</sup>	13
2b	H	H	H	Me	79	21 <sup>a</sup>	10c
2c	H	H	H	Br	70	# <sup>c</sup>	9d, 9e
2d	F	H	H	H	81	# <sup>c</sup>	10d, 10e
2e	H	H	H	CF <sub>3</sub>	66		nd
2f	H	H	H	NO <sub>2</sub>	74	100 <sup>a*</sup>	10a
2g	H	H	H	OH	74	# <sup>c</sup>	10b
2h	H	H	H	OMe	87	58 <sup>b</sup>	9d
2i	H	Me	H	H	87	61 <sup>a</sup>	10c
2j	H	H	Br	H	80	45 <sup>a</sup>	10c
2k	H	F	H	H	86	40 <sup>a</sup>	10c
2l	H	NO <sub>2</sub>	H	H	70	# <sup>c</sup>	9d, 9e
2m	H	H	OH	H	73	27 <sup>b</sup>	10f
2n	H	H	OMe	H	85	73 <sup>a</sup>	16a
2o	OMe	H	H	OMe	67		nd
2p	H	OMe	OMe	H	80	53 <sup>a</sup>	14c

<sup>a</sup>: yield described from the corresponding indanone; the oxidation method could be different; <sup>b</sup>: yield not described from the corresponding indanone; yield described from the corresponding indane-1,3-dione; <sup>c</sup>: yield not specified; <sup>\*</sup>: described without any purification; nd : not described

## Acknowledgments

The authors are grateful to Rhône-Alpes region for the microwave acquisition. M. Abdelhamid Nacereddine thanks the Algerian Ministry of Foreign Affairs and the Institut Français d'Algérie for his doctoral fellowship.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet>.

## References and notes

- Sarno, S.; Ghisellini, P.; Pinna, L.A. *J. Biol. Chem.* **2002**, *277*, 22509-22514.
- Guerra, B.; Issinger, O.-G. *Curr. Med. Chem.* **2008**, *15*, 1870-1886.
- (a) Gyenis, L.; Kuš, A.; Bretner, M.; Litchfield, D. W. *J. Proteomics.* **2013**, *81*, 70-79. (b) Unger, G. M.; Davis, A. T.; Slaton, J. W.; Ahmed, K. *Curr. Cancer Drug Targets* **2004**, *4*, 77-84. (c) Ahmad, K.A.; Wang, G.; Slaton, J.; Unger, G.; Ahmed, K. *Anticancer Drugs* **2005**, *16*, 1037-1043. (d) Landesman-Bollag, E.; Romieu-Mourez, R.; Song, D. H.; Sonenshein, G. E.; Cardiff, R. D.; Seldin, D. C. *Oncogene* **2001**, *20*, 3247-3257. (e) Yenice, S.; Davis, A. T.; Goueli, S. A.; Akdas, A.; Limas, C.; Ahmed, K. *Prostate* **1994**, *24*, 11-16. (f) Daya-Makin, M.; Sanghera, J. S.; Mogentale, T.; Lipp, M.; Parchomchuk, J.; Hogg J.; Pelech, S. L. *Cancer Res.* **1994**, *54*, 2262-2268. (g) Stalter, G.; Siemer, S.; Becht, E.; Ziegler, M.; Remberger, K.; Issinger, O. G. *Biochem. Biophys. Res. Commun.* **1994**, *202*, 141-147.
- (a) Cozza, G.; Pinna L. A.; Moro S. *Curr. Med. Chem.* **2013**, *20*, 671-693. (b) Cozza, G.; Bortolato, A.; Menta, E.; Cavalletti, E.; Spinelli, S.; Moro, S. *Anticancer Agents Med. Chem.* **2009**, *9*, 778-786.
- Trembley, J. H.; Unger, G. M.; Korman, V. L.; Tobolt, D. K.; Kazimierczuk, Z.; Pinna, L. A.; Kren, B. T.; Ahmed, K. *Cancer lett.* **2012**, *315*, 48-58.
- Hundsdörfer, C.; Hemmerling, H.-J.; Götz, C.; Totzke, F.; Bednarski, P.; Le Borgne, M.; Jose, J. *Bioorg. Med. Chem.* **2012**, *20*, 2282-2289.
- (a) Hemmerling, H. J.; Reiss, G. *Synthesis* **2009**, *6*, 985-999. (b) Hemmerling, H. J.; Reiss, G.; Götz, C.; Jose, J. WO 2008040547, **2008**. (c) Hemmerling, H. J.; Merschenz-Quack, A.; Wunderlich, H. Z. *Naturforsch., B: Chem. Sci.* **2004**, *59*, 1143-1152.
- Ruhemann, S. *Trans. Chem. Soc.* **1910**, *97*, 1438-1449.
- (a) Hark, R. R.; Hauze, D. B.; Petrovskiaia, O.; Hansen, D. B.; Joullié, M. M. *Chem. Soc. Rev.* **2005**, *34*, 408-417. (b) Joullié, M. *Can. J. Chem.* **2001**, *79*, 1632-1654. (c) Joullié, M. M.; Thompson, R. R.; Nemerooff, N. H. *Tetrahedron* **1991**, *47*, 8791-8830. (d) Lennard, C. J.; Margot, P. A.; Stoilovic, M.; Warrener, R. N. *J. For. Sci. Soc.* **1986**, *26*, 323-328. (e) Lennard, C. J.; Margot, P. A.; Stoilovic, M.; Warrener, R. N. *J. For. Sci. Soc.* **1988**, *28*, 3-23.
- (a) Jung, Y. S.; Lee, C. K.; Choi, I. Y.; Kim, H. S.; Kim, P. H.; Han, S. B.; Neyts, J.; Thibaut, H. J. *Eur. Pat.* 2,722,322, **2014**. (b) Jung, Y. S.; Lee, C. K.; Kim, H. S.; Jeong, H. C.; Kim, P. H.; Han, S. B.; Shin, J. S.; Neyts, J.; Thibaut, H. J. *Eur. Pat.* 2,722,042, **2014**. (c) Zhang, Z.; Du, X.; Chopiuk, G. *PCT Int. WO 02/02562, 2002*. (d) Desquand, S.; Finet, M.; Le Maquer, F.; Tembo, N. O.; Torregrosa, J.-L.; Yannic-Arnoult, S. *Eur. Pat.* 0,646,579, **1995**. (e) Desquand, S.; Finet, M.; Le Maquer, F.; Tembo, N. O.; Torregrosa, J.-L.; Yannic-Arnoult, S. *Eur. Pat.* 0,646,574, **1995**. (f) Cugnon de Sevrincourt, M.; Dacquet, C.; Finet, M.; Le Marquer, F.; Robba, M.; Tembo, N. O.; Yannic-Arnoult, S.; Torregrosa, J.-L. *Eur. Pat.* 0,566,446, **1993**.
- (a) Sharma, A. K.; Subramani, A. V.; Gorman C. B. *Tetrahedron* **2007**, *63*, 389-395. (b) Levy, J.-N.; Latham, C. M.; Roisin, L.; Kandziora, N.; Di Fruscia, P.; White, A. J. P.; Woodward, S.; Fuchter, M. J. *Org. and Biomol. Chem.* **2012**, *10*, 512-515. (c) Kamiya, N.; Tomonaga, A.; Sugiyama, H. *Eur. Pat.* 2,647,622, **2013**. (d) Chow, K.; Fang W. K.; Corpuz, E.; Gil D. W.; Garst, M. E. *US. Pat.* 0,255,230, **2008**. (e) Nguyen, P.; Corpuz, E.; Heidelbaugh, T. M.; Chow, K.; Garst, M. E. *J. Org. Chem.* **2003**, *68*, 10195-10198.
- Rubin, M. B.; Gleiter, R. *Chem. Rev.* **2000**, *100*, 1121-1164.
- Bowden, K.; Rumpal, S. *J. Chem. Res. Miniprint* **1997**, 355-363.
- (a) Tatsugi, J.; Izawa, Y. *Synthetic Comm.* **1998**, *28*, 859-864. (b) Heffner, R. J.; Joullié, M. M. *Synth. Comm.* **1991**, *21*, 2231-2256. (c) Maslak, P.; Chopra, A.; Moylan, C. R.; Wortmann, R.; Lebus, S.; Rheingold, A. L.; Yap, G. P. A. *J. Am. Chem. Soc.* **1996**, *118*, 1471-1481.
- (a) Smith, M. B. *Organic Synthesis Int. Ed.*; McGraw-Hill Int. Ed.: Singapore, **1994**, 311. (b) Sharpless, K. B.; Gordon, K. M. *J. Am. Chem. Soc.* **1976**, *98*, 300-301.
- (a) Reniers, J.; Meinguet, C.; Moineaux, L.; Masereel, B.; Vincent, S.P.; Frédéric, R.; Wouters, J. *Eur. J. Med. Chem.* **2011**, *46*, 6104-11. (b) Frédéric, R.; Dumont, W.; Ooms, F.; Aschenbach, L.; Van der Schyf, C. J.; Castagnoli, N.; Wouters, J.; Krief, A. *J. Med. Chem.* **2006**, *49*, 3743-3747.
- (a) Loupy, A. *Microwaves in Organic Synthesis 2d ed.*; Wiley-VCH: Weinheim, **2006**. (b) Di Fabio, G.; Romanucci, V.; De Nisco, M.; Pedatella, S.; Di Marino, C.; Zarrelli, A. *Tetrahedron Lett.* **2013**, *54*, 6279-6282. (c) Bagley, M. C.; Lin, Z.; Pope, S. J.-A. *Tetrahedron Lett.* **2009**, *50*, 6818-6822. (d) Hosseini, A.; Halvagar, M. R.; Khalilzadeh, M. A.; Alaee, E.; Tajbakhsh, M. *J. Chem. Res.* **2005**, *1*, 48-49.

17. (a) Young, R. M.; Davies-Coleman, M. T. *Tetrahedron Lett.* **2011**, *52*, 4036-4038. (b) Gelman, D. M.; Perlmutter, P. *Tetrahedron Lett.* **2009**, *50*, 39-40. (c) Olomola, T. O.; Klein, R.; Kaye, P. T. *Synthetic Comm.* **2012**, *42*, 251-257. (d) Avijit, K. A.; Shyamaprosad, G. *Synthetic Comm.* **2003**, *33*, 475-480. (e) Nagaraj, M.; Sathiyamoorthy, S.; Boominathan, M.; Muthusubramanian S.; Bhuvanesh N. *J. Heterocyclic Chem.* **2013**, *50*, 1146-1151.
18. *General experimental procedure for the synthesis of the ninhydrins (2)*: A sealed-pressurised reaction vessel (5 mL) equipped with a magnetic stirrer was charged with indan-1-one (1 eq.), selenium dioxide (3.1 eq.) and dioxane/water (3 mL/0.3 mL). It was then irradiated in a Biotage Initiator Microwave synthesizer

2.0 440 W with microwave heating to 180 °C with a maximum of 400 W for 5 minutes. Then, the vessel was rapidly forced-air cooled to room temperature. The mixture was transferred into a round bottom flask, and the vessel washed with acetone. Silica was added to prepare a solid deposit. The volatile solvents were then evaporated *in vacuo* before purification by flash chromatography (ethyl acetate / cyclohexane) to afford the corresponding ninhydrin.